Business Wire

CA-SANDBOX-VR

3.9.2024 15:01:35 CEST | Business Wire | Press release

Share
Sandbox VR Leans Into Franchise; 60% Deal Growth and Plans for 280 New Franchise Locations to Come

Sandbox VR, the world's premier destination for premium location-based virtual reality experiences, is announcing significant growth milestones of its franchise program. The company saw 60% growth in franchise deals in Q2 with plans to open 280 new franchise locations in the next four years. This announcement comes on the heels of opening their 50th store on August 15. Located on the Gold Coast, the new location is the first Sandbox VR in Australia, expanding its global presence to four continents and nine countries.

Since opening its first store in Hong Kong in 2017, Sandbox VR has rapidly grown its global footprint with thriving corporate-owned locations and a robust franchising program. Today, its global locations see over 100k players monthly. In 2023, the company topped 1.2M tickets sold and has seen a 33% year-over-year increase in 2024 ticket sales. Sandbox VR’s corporate locations—37 in total—hit a revenue milestone with an average store topping $1.9M annually.

Sandbox VR's franchise program launched in 2019 for international markets and opened up for US territories in April of this year. In those four months, 33% of available Sandbox VR US franchise territories have been claimed by new and existing franchise partners. Franchising has been instrumental in making Sandbox VR the fastest growing location-based VR startup globally, and this US momentum signals continued rapid growth. Limited opportunities for prime locations and territory exclusivity are still available in the US.

“When I started building Sandbox VR, I set out to build the future of entertainment. I never would have succeeded without the right team of people helping me build the world's most immersive experiences using bleeding edge virtual reality technology,” said Steve Zhao, CEO and founder of Sandbox VR. “As we set our sights on expanding globally, we know it’s critical to work with the right partners. We are thrilled to announce the 50th Sandbox VR location in collaboration with our franchise partners, Bao Phung and Keith Le, and look forward to working with passionate franchise partners from around the globe to open hundreds more in the next four years.”

“We considered a different location-based virtual reality company when it came to exploring our franchise opportunities but ultimately determined that we wanted to partner with Sandbox VR, the leader in the category,” said Bao Phung, Owner of Sandbox VR Gold Coast. “Partnering with Sandbox VR was the most advantageous and strategic decision for our business, allowing us to introduce Australia to immersive games you can’t play anywhere else on the world’s most immersive full-body VR platform. The Gold Coast, which attracts 13 million visitors annually, is the natural choice for our first location. We look forward to introducing locals and visitors alike to a whole new reality.”

Sandbox VR’s UK and Ireland franchise partners, VR Entertainment Group, are proof of the strength of the Sandbox VR franchise program. Since launching their first store in London in July 2022—and their second in Birmingham a year later—they have surpassed the $10M revenue milestone. In London alone, VR Entertainment Group has seen a 16.8% increase in guests year-to-date and projects their 2024 revenue to top $5M.

“I believe our success is due to the strength of our partnership with Sandbox VR,” said Andy Scanlon, co-founder and CEO of VR Entertainment Group. “Their world class VR, brand, and wider corporate team, with our local expertise and determination to build Sandbox VR into the leading immersive entertainment brand in the UK & Ireland, has led to a nexus delivering truly amazing experiences for our guests.”

Sandbox VR is creating the future of entertainment by building the world’s most immersive experiences using proprietary virtual reality technology. Their patented motion-tracking system, which captures the movements of a player’s entire body, combines with high-quality haptics to provide players with unprecedented realism and complete immersion that’s not possible with home VR or other location-based VR platforms. Guests’ own bodies act as their game controllers; all they have to do is step into the virtual world and participate in the action unfolding all around them.

All Sandbox VR experiences—eight in total—are developed by in-house AAA gaming studios in Hong Kong and Vancouver, led by game industry veterans and are specifically designed for groups to play as social experiences. Teams of up to six freely roam and explore virtual worlds together, while relying on each other to succeed.

For more information and to make reservations, please visit sandboxvr.com. To learn more about Sandbox VR franchise opportunities, please visit https://franchise.sandboxvr.com/.

ABOUT SANDBOX VR

Sandbox VR is the world's premier destination for premium, location-based virtual reality games. The company has created the world’s most immersive full-body VR platform and boasts exclusive games, including original and branded experiences, such as Squid Game Virtuals, created in collaboration with Netflix. Now operating in 50 locations and attracting over 100k players monthly, Sandbox VR is rapidly growing its global footprint with thriving corporate-owned locations and a robust franchising program. The company has been recognized as one of Fast Company’s 2024 Most Innovative Companies and is the 129th fastest growing company in America on the 2024 Inc. 5000 list. Sandbox VR is headquartered in San Francisco, California with offices in Hong Kong and Vancouver. The company’s latest round raised over $37 million from investors including Andreessen Horowitz, Alibaba Entrepreneurs Fund, Gobi Partners, and Craft. Individual investors include Justin Timberlake, Katy Perry, Kevin Durant and Will Smith.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903348064/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye